Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells

Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate synthase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullah, Marwan Ibrahim, Abed, Mohammed Najim, Richardson, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556066/
https://www.ncbi.nlm.nih.gov/pubmed/28808351
http://dx.doi.org/10.1038/s41598-017-08649-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556066/
https://www.ncbi.nlm.nih.gov/pubmed/28808351
http://dx.doi.org/10.1038/s41598-017-08649-9

Ejemplares similares